Skip to main content

Search

Show all results for

Home

Person

Camille Villequey

This person is no longer with EPFL

About
Privacy
Disclaimer

Copyright © 2025 EPFL, all rights reserved

Graph Chatbot

About this result

This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.

Related publications (4)

Please note that this is not a complete list of this person’s publications. It includes only semantically relevant works. For a full list, please refer to Infoscience.

Development of Selective FXIa Inhibitors Based on Cyclic Peptides and Their Application for Safe Anticoagulation

Christian Heinis, Chloé Rogg, Xudong Kong, Vanessa Carle, Cristina Diaz Perlas, Camille Villequey, Tamara Maric, Kaycie Marie Butler, Christina Lamers

Coagulation factor XI (FXI) has emerged as a promising target for the development of safer anticoagulation drugs that limit the risk of severe and life-threatening bleeding. Herein, we report the first cyclic peptide-based FXI inhibitor that selectively an ...

2021

Cyclization of peptides with two chemical bridges affords large scaffold diversities

Christian Heinis, Xudong Kong, Alessandro Zorzi, Sangram Shivdas Kale, Camille Villequey

2018

New methods for developing (bi)cyclic peptides by phage display

Camille Villequey

Cyclic peptide ligands are a promising molecular format for the development of therapeutics. They combine some of the advantages of large protein therapeutics (high affinity and specificity) and of small molecule drugs (accessibility to chemical synthesis ...

EPFL2017